Learn what proteolysis-targeting chimeras (PROTACs) are, how they work as small-molecule protein degraders, and why they outperform classic inhibitors by accessing undruggable targets, driving deep protein knockdown, and enabling next-generation cancer therapies like ARV-110.
Learn how PROTACs (Proteolysis-Targeting Chimeras) work, why they can target “undruggable” cancer proteins, and how small molecule degraders like ARV-110 and ARV-471 are changing oncology treatment.